

# Polypoidal choroidal vasculopathy - Pipeline Insight, 2021

<https://marketpublishers.com/r/P4B4BE42847DEN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P4B4BE42847DEN

## Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Polypoidal choroidal vasculopathy - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Polypoidal choroidal vasculopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

## Geography Covered

Global coverage

Polypoidal choroidal vasculopathy Understanding

Polypoidal choroidal vasculopathy: Overview

Polypoidal choroidal vasculopathy (PCV) is a neovascular AMD which is presented by multiple recurrent serosanguinous maculopathy or bilateral detachment of retinal pigment epithelial (PED). This condition is due to abnormality of inner choroidal vessel and tends to cause polypoidal protrusions. Individuals with cardiovascular abnormalities, diabetes mellitus, obstructive sleep apnoea, and ocular abnormalities such as choroidal thickening are likely to be associated with PCV. PVC is more prevalent among the Asian and African population and largely affects male in comparison to females with a mean age of 61 years. Photodynamic therapy and anti-

VEGF agents alone or in combination can be used to treat PVC to some extent.

“Polypoidal choroidal vasculopathy - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Polypoidal choroidal vasculopathy pipeline landscape is provided which includes the disease overview and Polypoidal choroidal vasculopathy treatment guidelines. The assessment part of the report embraces, in depth Polypoidal choroidal vasculopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polypoidal choroidal vasculopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## **Report Highlights**

The companies and academics are working to assess challenges and seek opportunities that could influence Polypoidal choroidal vasculopathy R&D. The therapies under development are focused on novel approaches to treat/improve Polypoidal choroidal vasculopathy.

### **Polypoidal choroidal vasculopathy Emerging Drugs Chapters**

This segment of the Polypoidal choroidal vasculopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### **Polypoidal choroidal vasculopathy Emerging Drugs**

#### **Aflibecept: Bayer AG**

Aflibercept is a recombinant fusion protein. It is currently under Phase III development for the treatment of polypoidal choroidal vasculopathy. It is an anti-VEGF molecule that binds to the freely floating VEGF and inhibit the activity of VEGF A and VEGF B as well as placental growth factor.

#### **Zimura: IVERIC Bio, Inc.**

Zimura is a polyethylene glycol that inhibits the cleavage of C5 fragment into C5a and C5b. The molecule is in Phase II of the clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy.

Further product details are provided in the report.....

### Polypoidal choroidal vasculopathy: Therapeutic Assessment

This segment of the report provides insights about the different Polypoidal choroidal vasculopathy drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in Polypoidal choroidal vasculopathy

There are approx. 4+ key companies which are developing the therapies for Polypoidal choroidal vasculopathy. The companies which have their Polypoidal choroidal vasculopathy drug candidates in the most advanced stage, i.e. phase III include, Bayer AG.

### Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

### Route of Administration

Polypoidal choroidal vasculopathy pipeline report provides the therapeutic assessment

of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

## **Product Type**

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Polypoidal choroidal vasculopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Polypoidal choroidal vasculopathy therapeutic drugs key players involved in developing key drugs.

## Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Polypoidal choroidal vasculopathy drugs.

### Polypoidal choroidal vasculopathy Report Insights

Polypoidal choroidal vasculopathy Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

### Polypoidal choroidal vasculopathy Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Polypoidal choroidal vasculopathy drugs?

How many Polypoidal choroidal vasculopathy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Polypoidal choroidal vasculopathy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Polypoidal choroidal vasculopathy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Polypoidal choroidal vasculopathy and their status?

What are the key designations that have been granted to the emerging drugs?

## **Key Players**

Bayer AG

IVERIC bio, Inc.

Novartis

## **Key Products**

Aflibecept

Zimura

Ranibizumab

## Contents

Introduction

Executive Summary

Polypoidal choroidal vasculopathy: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Polypoidal choroidal vasculopathy – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Polypoidal choroidal vasculopathy companies' collaborations, Licensing, Acquisition  
-Deal Value Trends

Polypoidal choroidal vasculopathy Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Aflibercept: Bayer AG

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Zimura: IVERIC bio, Inc.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Polypoidal choroidal vasculopathy Key Companies

Polypoidal choroidal vasculopathy Key Products

Polypoidal choroidal vasculopathy- Unmet Needs

Polypoidal choroidal vasculopathy- Market Drivers and Barriers

Polypoidal choroidal vasculopathy- Future Perspectives and Conclusion

Polypoidal choroidal vasculopathy Analyst Views

Polypoidal choroidal vasculopathy Key Companies

Appendix



## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Polypoidal choroidal vasculopathy

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Polypoidal choroidal vasculopathy

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Polypoidal choroidal vasculopathy - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P4B4BE42847DEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P4B4BE42847DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970